Literature DB >> 24978328

Correlation between PET/CT parameters and KRAS expression in colorectal cancer.

Shang-Wen Chen1, Hua-Che Chiang, William Tzu-Liang Chen, Te-Chun Hsieh, Kuo-Yang Yen, Shu-Fen Chiang, Chia-Hung Kao.   

Abstract

PURPOSE: The objective of this study was to correlate the association between mutated KRAS and wild-type colorectal cancer (CRC) by using various F-FDG PET-related parameters.
METHODS: One hundred twenty-one CRC patients who had undergone preoperative PET/CT were included in this study. Several PET/CT-related parameters, including SUVmax and various thresholds of metabolic tumor volume, total lesion glycolysis, and PET/CT-based tumor width, were measured. Tumor- and PET/CT-related parameters were correlated with genomic expression between KRAS mutant and wild-type groups, using a Mann-Whitney U test and logistic regression analysis.
RESULTS: Colorectal cancer tumors with a mutated KRAS exhibited higher SUVmax and an increased accumulation of FDG among several threshold methods. Multivariate analysis showed that SUVmax and using a 40% threshold level for maximal uptake of TW (TW40%) were the 2 predictors of KRAS mutations. The odds ratio was 1.23 for SUVmax (P = 0.02; 95% confidence interval, 1.01-1.52) and 1.15 for TW40% (P = 0.02; 95% confidence interval, 1.02-1.30). The accuracy of SUVmax for predicting mutated KRAS was higher in patients with colon or sigmoid colon cancers, whereas it was TW40% in those with rectal cancers.
CONCLUSIONS: SUVmax and TW40% were associated in CRC with KRAS mutations. PET/CT parameters can supplement genomic analysis to determine KRAS expression in CRC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24978328     DOI: 10.1097/RLU.0000000000000481

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  23 in total

1.  A chirality-dependent action of vitamin C in suppressing Kirsten rat sarcoma mutant tumor growth by the oxidative combination: Rationale for cancer therapeutics.

Authors:  Xinggang Wu; Mikyung Park; Dilara A Sarbassova; Haoqiang Ying; Min Gyu Lee; Rajat Bhattacharya; Lee Ellis; Christine B Peterson; Mien-Chie Hung; Hui-Kuan Lin; Rakhmetkazhi I Bersimbaev; Min Sup Song; Dos D Sarbassov
Journal:  Int J Cancer       Date:  2019-10-08       Impact factor: 7.396

2.  Lung metastasectomy after colorectal cancer: prognostic impact of resection margin on long term survival, a retrospective cohort study.

Authors:  Federico Davini; Sara Ricciardi; Carmelina C Zirafa; Gaetano Romano; Greta Alì; Gabriella Fontanini; Franca M A Melfi
Journal:  Int J Colorectal Dis       Date:  2019-11-04       Impact factor: 2.571

Review 3.  Targeting metabolic reprogramming in KRAS-driven cancers.

Authors:  Kenji Kawada; Kosuke Toda; Yoshiharu Sakai
Journal:  Int J Clin Oncol       Date:  2017-06-24       Impact factor: 3.402

4.  Predicting Kirsten Rat Sarcoma Virus Gene Mutation Status in Patients With Colorectal Cancer by Radiomics Models Based on Multiphasic CT.

Authors:  Jianfeng Hu; Xiaoying Xia; Peng Wang; Yu Peng; Jieqiong Liu; Xiaobin Xie; Yuting Liao; Qi Wan; Xinchun Li
Journal:  Front Oncol       Date:  2022-06-24       Impact factor: 5.738

Review 5.  Novel imaging techniques of rectal cancer: what do radiomics and radiogenomics have to offer? A literature review.

Authors:  Natally Horvat; David D B Bates; Iva Petkovska
Journal:  Abdom Radiol (NY)       Date:  2019-11

6.  (18)F-FDG PET/CT imaging in rectal cancer: relationship with the RAS mutational status.

Authors:  Pierre Lovinfosse; Benjamin Koopmansch; Frederic Lambert; Sébastien Jodogne; Gaelle Kustermans; Mathieu Hatt; Dimitris Visvikis; Laurence Seidel; Marc Polus; Adelin Albert; Philippe Delvenne; Roland Hustinx
Journal:  Br J Radiol       Date:  2016-05-05       Impact factor: 3.039

7.  Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?

Authors:  Lei Yang; Di Dong; Mengjie Fang; Yongbei Zhu; Yali Zang; Zhenyu Liu; Hongmei Zhang; Jianming Ying; Xinming Zhao; Jie Tian
Journal:  Eur Radiol       Date:  2018-01-15       Impact factor: 5.315

8.  Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH.

Authors:  Jihye Yun; Edouard Mullarky; Changyuan Lu; Kaitlyn N Bosch; Adam Kavalier; Keith Rivera; Jatin Roper; Iok In Christine Chio; Eugenia G Giannopoulou; Carlo Rago; Ashlesha Muley; John M Asara; Jihye Paik; Olivier Elemento; Zhengming Chen; Darryl J Pappin; Lukas E Dow; Nickolas Papadopoulos; Steven S Gross; Lewis C Cantley
Journal:  Science       Date:  2015-11-05       Impact factor: 47.728

9.  MRI Radiomics Signature as a Potential Biomarker for Predicting KRAS Status in Locally Advanced Rectal Cancer Patients.

Authors:  ZhiYuan Zhang; LiJun Shen; Yan Wang; Jiazhou Wang; Hui Zhang; Fan Xia; JueFeng Wan; Zhen Zhang
Journal:  Front Oncol       Date:  2021-05-07       Impact factor: 6.244

Review 10.  The application of radiomics in predicting gene mutations in cancer.

Authors:  Yana Qi; Tingting Zhao; Mingyong Han
Journal:  Eur Radiol       Date:  2022-01-20       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.